An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
OBJECTIVE Though doxorubicin is highly active in the treatment of multiple myeloma, its toxicity profile limits its therapeutic index. We performed this study to evaluate the effi cacy and safety of pegylated liposomal doxorubicin (PLD, Caelyx®), vincristine, and reduced-dose dexamethasone combi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2009-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/244 |
| _version_ | 1817978359639965696 |
|---|---|
| author | Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG |
| author_facet | Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG |
| author_sort | Yang SHEN, Zhixiang SHEN, Bin JIANG |
| collection | DOAJ |
| description | OBJECTIVE Though doxorubicin is highly active in the treatment of multiple myeloma, its toxicity profile limits its therapeutic index. We performed this study to evaluate the effi cacy and safety of pegylated liposomal doxorubicin (PLD, Caelyx®), vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma (MM) patients in a Chinese population. METHODS This was an open-label, single-arm study in which newly diagnosed patients with MM received PLD 40 mg/m2 intravenously on Day 1, vincristine 1.4 mg/m2 intravenously (maximum 2 mg) on Day 1, and 40 mg of dexamethasone (intravenously or orally) from Day 1 to Day 4. Treatment was repeated every 28 days for at least 4 cycles. RESULTS In the intent-to-treat (ITT) analysis, the overall response rate was 68.29%, and the complete remission rate was 10.98%. The incidence of all adverse events was 46.34%. The most common non-hematologic toxicities were palmar-plantar erythrodysesthesia (13.4%) and stomatitis (6.1%). CONCLUSION PLD, vincristine, and a reduced-dose dexamethasone combination (DVd) is an effective and safe regimen in newly diagnosed MM patients in a Chinese population. |
| first_indexed | 2024-04-13T22:29:06Z |
| format | Article |
| id | doaj.art-f08844c7a906477d84228ff129d7402a |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-04-13T22:29:06Z |
| publishDate | 2009-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-f08844c7a906477d84228ff129d7402a2022-12-22T02:26:59ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412009-12-016639440010.1007/s11805-009-0394-2An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese PopulationYang SHEN, Zhixiang SHEN, Bin JIANGYang SHEN, Zhixiang SHEN, Bin JIANGYang SHEN, Zhixiang SHEN, Bin JIANGOBJECTIVE Though doxorubicin is highly active in the treatment of multiple myeloma, its toxicity profile limits its therapeutic index. We performed this study to evaluate the effi cacy and safety of pegylated liposomal doxorubicin (PLD, Caelyx®), vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma (MM) patients in a Chinese population. METHODS This was an open-label, single-arm study in which newly diagnosed patients with MM received PLD 40 mg/m2 intravenously on Day 1, vincristine 1.4 mg/m2 intravenously (maximum 2 mg) on Day 1, and 40 mg of dexamethasone (intravenously or orally) from Day 1 to Day 4. Treatment was repeated every 28 days for at least 4 cycles. RESULTS In the intent-to-treat (ITT) analysis, the overall response rate was 68.29%, and the complete remission rate was 10.98%. The incidence of all adverse events was 46.34%. The most common non-hematologic toxicities were palmar-plantar erythrodysesthesia (13.4%) and stomatitis (6.1%). CONCLUSION PLD, vincristine, and a reduced-dose dexamethasone combination (DVd) is an effective and safe regimen in newly diagnosed MM patients in a Chinese population.http://www.cancerbiomed.org/index.php/cocr/article/view/244pegylated liposomal doxorubicinmultiple myelomachemotherapy. |
| spellingShingle | Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG Yang SHEN, Zhixiang SHEN, Bin JIANG An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population Cancer Biology & Medicine pegylated liposomal doxorubicin multiple myeloma chemotherapy. |
| title | An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population |
| title_full | An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population |
| title_fullStr | An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population |
| title_full_unstemmed | An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population |
| title_short | An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population |
| title_sort | open label study of pegylated liposomal doxorubicin vincristine and reduced dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the chinese population |
| topic | pegylated liposomal doxorubicin multiple myeloma chemotherapy. |
| url | http://www.cancerbiomed.org/index.php/cocr/article/view/244 |
| work_keys_str_mv | AT yangshenzhixiangshenbinjiang anopenlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation AT yangshenzhixiangshenbinjiang anopenlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation AT yangshenzhixiangshenbinjiang anopenlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation AT yangshenzhixiangshenbinjiang openlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation AT yangshenzhixiangshenbinjiang openlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation AT yangshenzhixiangshenbinjiang openlabelstudyofpegylatedliposomaldoxorubicinvincristineandreduceddosedexamethasonecombinationtherapyinnewlydiagnosedmultiplemyelomapatientsinthechinesepopulation |